Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.

Issue 15, 2018
Previous Article Next Article

nCVTs: a hybrid smart tumour targeting platform

Author affiliations


A hybrid drug delivery platform involving the fusion of cell membranes from U937 monocytes and synthetic lipids to create nano-cell vesicle technology systems (nCVTs) is designed. nCVTs are engineered for a targeted approach towards tumour sites by preserving key surface proteins from U937 monocytes, while being amendable to functionalization and loading due to their liposomal components.

Graphical abstract: nCVTs: a hybrid smart tumour targeting platform

Back to tab navigation

Supplementary files

Article information

22 Nov 2017
08 Mar 2018
First published
13 Mar 2018

Nanoscale, 2018,10, 6812-6819
Article type

nCVTs: a hybrid smart tumour targeting platform

W. J. Goh, S. Zou, B. Czarny and G. Pastorin, Nanoscale, 2018, 10, 6812
DOI: 10.1039/C7NR08720A

Social activity

Search articles by author